Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation

Stopped early · Phase 1/Phase 2

Conditions studied: Kidney Transplant

In brief

The purpose of this study is to try to determine if the drug eculizumab can help prevent antibody-mediated rejection in patients undergoing a kidney transplant from a living donor with a different blood type than their own.

Key facts

Study ID

NCT01095887

Run by

Mayo Clinic

People needed

6

Starts

2010-05-01

Expected to finish

2014-04-01

Last updated by the study team

2015-07-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Be at least 18 years of age
• Have end stage renal disease (ESRD) and is receiving a kidney transplant from a living donor to whom he/she has a baseline anti-blood group titer >1:32
• Be vaccinated against N. meningitides (quadrivalent vaccine), H. Flu, and pneumococcal disease at least two weeks prior to beginning desensitization.

You may not qualify if…

• Has an unstable cardiovascular condition
• Has had a previous splenectomy
• Has any active bacterial or other infection
• Has a known or suspected hereditary complement deficiency
• Has known hypersensitivity to the treatment drug or any of its excipients
• Has history of illicit drug use or alcohol abuse within the previous year
• Has history of meningococcal disease
• Has any medical condition that, in the opinion of the investigator, might interfere with the patient's participation in the study, pose an added risk for the patient, or confound the assessment of the patient (e.g. severe cardiovascular or pulmonary disease)

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.